These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
215 related articles for article (PubMed ID: 8862446)
21. Cytosine arabinoside (ara-C) resistance confers cross-resistance or collateral sensitivity to other classes of anti-leukemic drugs. Martin-Aragon S; Mukherjee SK; Taylor BJ; Ivy SP; Fu CH; Ardi VC; Avramis VI Anticancer Res; 2000; 20(1A):139-50. PubMed ID: 10769646 [TBL] [Abstract][Full Text] [Related]
22. Gene transfer of cytidine deaminase protects myelopoiesis from cytidine analogs in an in vivo murine transplant model. Rattmann I; Kleff V; Sorg UR; Bardenheuer W; Brueckner A; Hilger RA; Opalka B; Seeber S; Flasshove M; Moritz T Blood; 2006 Nov; 108(9):2965-71. PubMed ID: 16835384 [TBL] [Abstract][Full Text] [Related]
23. Induction of resistance to the lipophilic cytarabine prodrug elacytarabine (CP-4055) in CEM leukemic cells. Adema AD; Losekoot N; Smid K; Kathmann I; Myhren F; Sandvold ML; Peters GJ Nucleosides Nucleotides Nucleic Acids; 2010 Jun; 29(4-6):394-9. PubMed ID: 20544525 [TBL] [Abstract][Full Text] [Related]
24. Chemoprotection against cytosine nucleoside analogs using the human cytidine deaminase gene. Eliopoulos N; Beauséjour C; Momparler RL Prog Exp Tumor Res; 1999; 36():124-42. PubMed ID: 10386070 [No Abstract] [Full Text] [Related]
25. Combinations of tetrahydrouridine and cytosine arabinoside in mouse tumors. Kreis W; Hession C; Soricelli A; Scully K Cancer Treat Rep; 1977 Oct; 61(7):1355-64. PubMed ID: 589601 [TBL] [Abstract][Full Text] [Related]
26. Modulation of the effect of 1-beta-D-arabinofuranosylcytosine based on changes of cytidine deaminase activity in HL60 cells. Mejer JN; Mortensen BT; Christensen IJ Med Oncol Tumor Pharmacother; 1990; 7(1):25-9. PubMed ID: 2338846 [TBL] [Abstract][Full Text] [Related]
27. The synergistic interaction of gemcitabine and cytosine arabinoside with the ribonucleotide reductase inhibitor triapine is schedule dependent. Sigmond J; Kamphuis JA; Laan AC; Hoebe EK; Bergman AM; Peters GJ Biochem Pharmacol; 2007 May; 73(10):1548-57. PubMed ID: 17324380 [TBL] [Abstract][Full Text] [Related]
28. GATA1, cytidine deaminase, and the high cure rate of Down syndrome children with acute megakaryocytic leukemia. Ge Y; Stout ML; Tatman DA; Jensen TL; Buck S; Thomas RL; Ravindranath Y; Matherly LH; Taub JW J Natl Cancer Inst; 2005 Feb; 97(3):226-31. PubMed ID: 15687366 [TBL] [Abstract][Full Text] [Related]
29. Chemoprotection of murine hematopoietic cells by combined gene transfer of cytidine deaminase (CDD) and multidrug resistance 1 gene (MDR1). Brennig S; Lachmann N; Buchegger T; Hetzel M; Schambach A; Moritz T J Exp Clin Cancer Res; 2015 Dec; 34():148. PubMed ID: 26651614 [TBL] [Abstract][Full Text] [Related]
30. Pharmacogenomics of gemcitabine metabolism: functional analysis of genetic variants in cytidine deaminase and deoxycytidine kinase. Baker JA; Wickremsinhe ER; Li CH; Oluyedun OA; Dantzig AH; Hall SD; Qian YW; Ring BJ; Wrighton SA; Guo Y Drug Metab Dispos; 2013 Mar; 41(3):541-5. PubMed ID: 23230131 [TBL] [Abstract][Full Text] [Related]
31. Comparison of antineoplastic activity of 2',2'-difluorodeoxycytidine and cytosine arabinoside against human myeloid and lymphoid leukemic cells. Bouffard DY; Momparler LF; Momparler RL Anticancer Drugs; 1991 Feb; 2(1):49-55. PubMed ID: 1958852 [TBL] [Abstract][Full Text] [Related]
32. A bioluminescent microbial biosensor for in vitro pretreatment assessment of cytarabine efficacy in leukemia. Alloush HM; Anderson E; Martin AD; Ruddock MW; Angell JE; Hill PJ; Mehta P; Smith MA; Smith JG; Salisbury VC Clin Chem; 2010 Dec; 56(12):1862-70. PubMed ID: 20921267 [TBL] [Abstract][Full Text] [Related]
33. [Clinical pharmacology of nucleoside analogues]. Milano G; Chamorey AL; Thyss A Bull Cancer; 2002 Aug; 89 Spec No():S71-5. PubMed ID: 12449033 [TBL] [Abstract][Full Text] [Related]
34. Pharmacology of combination chemotherapy of cytosine arabinoside (ara-C) and uracil arabinoside (ara-U) or tetrahydrouridine (THU) against murine leukemia L1210/0 in tumor-bearing mice. Avramis VI; Powell W Cancer Invest; 1987; 5(4):293-9. PubMed ID: 3664332 [TBL] [Abstract][Full Text] [Related]
35. Effect of tetrahydrouridine and deoxytetrahydrouridine on the interaction between 2'-deoxycytidine and 1-beta-D-arabinofuranosylcytosine in human leukemia cells. Grant S; Bhalla K; McCrady C Leuk Res; 1991; 15(4):205-13. PubMed ID: 2030601 [TBL] [Abstract][Full Text] [Related]
36. The antiproliferative activity of DMDC is modulated by inhibition of cytidine deaminase. Eda H; Ura M; F-Ouchi K; Tanaka Y; Miwa M; Ishitsuka H Cancer Res; 1998 Mar; 58(6):1165-9. PubMed ID: 9515801 [TBL] [Abstract][Full Text] [Related]
37. Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines. Gourdeau H; Clarke ML; Ouellet F; Mowles D; Selner M; Richard A; Lee N; Mackey JR; Young JD; Jolivet J; Lafrenière RG; Cass CE Cancer Res; 2001 Oct; 61(19):7217-24. PubMed ID: 11585758 [TBL] [Abstract][Full Text] [Related]
38. Intracellular pharmacodynamic studies of the synergistic combination of 6-mercaptopurine and cytosine arabinoside in human leukemia cell lines. Ramilo-Torno LV; Avramis VI Cancer Chemother Pharmacol; 1995; 35(3):191-9. PubMed ID: 7805176 [TBL] [Abstract][Full Text] [Related]
39. Cellular pharmacology of gemcitabine. Mini E; Nobili S; Caciagli B; Landini I; Mazzei T Ann Oncol; 2006 May; 17 Suppl 5():v7-12. PubMed ID: 16807468 [TBL] [Abstract][Full Text] [Related]
40. Potent inhibitors for the deamination of cytosine arabinoside and 5-aza-2'-deoxycytidine by human cytidine deaminase. Laliberté J; Marquez VE; Momparler RL Cancer Chemother Pharmacol; 1992; 30(1):7-11. PubMed ID: 1375134 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]